A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL

Molecular Immunology

Volumn 33, Issue 2, 1996, Pages 211-219

  Jost, Carolina R ^a   Titus, Julie A ^a   Kurucz, Istvan ^a   Segal, David M ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

bispecific antibody; redirected lysis; single chain antibody

Indexed keywords

BISPECIFIC ANTIBODY; CD4 ANTIGEN; MONOCLONAL ANTIBODY; TRANSFERRIN RECEPTOR;

ANIMAL CELL; ARTICLE; CELL LINE; CYTOTOXIC T LYMPHOCYTE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029916960     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/0161-5890(95)00087-9     Document Type: Article

References (53)

1. Barnstable C. J., Bodmer W. F., Brown G., Galfre G., Milstein C., Williams A. F. and Ziegler A. (1978) Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens - new tools for genetic analysis. Cell 14, 9-20.
2. Berzofsky J. A., Berkower I. J. and Epstein S. L. (1993) Antigen-antibody interactions and monoclonal antibodies. In Fundamental Immunology (Edited by Paul W. E.), p. 421. Raven Press Ltd, New York.
3. Bird R. E., Hardman K. D., Jacobson J. W., Johnson S., Kaufman B. M., Lee S. M., Lee T., Pope S. H., Riordan G. S. and Whitlow M. (1988) Single-chain antigen-binding proteins. Science 242, 423-426.
4. Bolhuis R. L., Lamers C. H., Goey S. H., Eggermont A. M., Trimbos J. B., Stoter G., Lanzavecchia A., Di Re E., Miotti S., Raspagliesi F., Rivoltini L. and Colnaghi M. I. (1992) Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int. J. Cancer 7(suppl.), 78-81.
5. Brissinck J., Demanet C., Moser M., Leo O. and Thielemans K. (1991) Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J. Immun. 147, 4019-4026.
6. Carter P., Kelley R. F., Rodrigues M. L., Snedecor B., Covarrubias M., Velligan M. D., Wong W. L. T., Rowland A. M., Kotts C. E., Carver M. E., Yang M., Bourell J. H., Shepard H. M. and Henner D. (1992) High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology 10, 163-167.
7. Davis L. G., Dibner M. D. and Battey J. F. (1986) Basic Methods in Molecular Biology. Elsevier, New York.
8. De Lau W. B. M., Heije K., Neeges J. J., Oosterwegel M., Rozemuller E. and Bast B. J. E. G. (1991) Absence of preferential homologous H/L chain association in hybrid hybridomas. J. Immun. 146, 906-914.
9. Demanet C., Brissinck J., Van Mechelen M., Leo O. and Thielemans K. (1991) Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype × anti-CD3). J. Immun. 147, 1091-1097.
10. 1 lymphoma. Cancer Res. 54, 2973-2978.
11. Evan G. I., Lewis G. K., Ramsay G. and Bishop J. M. (1985) Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Molec. Cell Biol. 5, 3610-3616.
12. Garrido M. A., Valdayo M. J., Winkler D. F., Titus J. A., Hecht T. T., Perez P., Segal D. M. and Wunderlich J. R. (1990) Targeting human T lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells in nu/nu mice. Cancer Res. 50, 4227-4232.
13. Gething M. J. and Sambrook J. (1992) Protein folding in the cell. Nature 355, 33-45.
14. 2 antibody containing thioether-linked Fab′τ fragments. J. Immun. 139, 2367-2375.
15. Glockshuber R., Malia M., Pfitzinger I. and Pluckthun A. (1990) A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry. 29, 1362-1367.
16. Goding J. W. and Burns G. F. (1981) Monoclonal antibody OKT-9 recognizes the receptor for transferrin on human acute lymphocytic leukemia cells. J. Immun. 127, 1256-1258.
17. Gootenberg J. E., Ruscetti F. W., Mier J. W., Gazdar A. and Gallo R. C. (1981) Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J. exp. Med. 154, 1403-1418.
18. Gruber M., Schodin B. A., Wilson E. R. and Kranz D. M. (1994) Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J. Immun. 152, 5368-5374.
19. Hayden M. S., Linsley P. S., Gayle M. A., Bajorath J., Brady W. A., Norris N. A., Fell H. P., Ledbetter J. A. and Gilliland L. K. (1994) Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Therapeut. Immun. 1, 3-15.
20. Hedrick S. M., Matis L. A., Hecht T. T., Samelson L. E., Longo D. L., Heber-Katz E. and Schwartz R. H. (1982) The fine specificity of antigen and Ia determinant recognition by T cell hybridoma clones specific for pigeon cytochrome c. Cell 30, 141-152.
21. Holliger P., Prospero T. and Winter G. (1993) "Diabodies": small bivalent and bispecific antibody fragments. Proc. natn. Acad. Sci. U.S.A. 90, 6444-6448.
22. Holliger P. and Winter G. (1993) Engineering bispecific antibodies. Curr. Opin. Biotech. 4, 446-449.
23. Huston J. S., Levinson D., Mudgett-Hunter M., Tai M. S., Novotny J., Margolies M. N., Ridge R. J., Bruccoleri R. E., Haber E., Crea R. and Oppermann H. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. natn. Acad. Sci. U.S.A. 85, 5879-5883.
24. Huston J. S., McCartney J., Tai M.-S., Mottola-Hartshorn C., Jin D., Warren F., Keck P. and Oppermann H. (1993) Medical applications of single-chain antibodies. Int. Rev. Immun. 10, 195-217.
25. Jost C. R., Kurucz I., Jacobus C. M., Titus J. A., George A. J. T. and Segal D. M. (1994) Mammalian expression and secretion of functional single-chain Fv molecules. J. biol. Chem. 269, 26267-26273.
26. Kostelny S. A., Cole M. S. and Tso J. Y. (1992) Formation of a bispecific antibody by the use of leucine zippers. J. Immun. 148, 1547-1553.
27. Kroesen B. J., Ter Haar A., Spakman H., Willemse P., Sleijfer D. T., De Vries E. G. E., Mulder N. H., Berendsen H. H., Limburg P. C., The T. H. and De Leij L. (1993) Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immun. Immunother. 37, 400-407.
28. Kurucz I., Titus J. A., Jost C. R., Jacobus C. M. and Segal D. M. (1995) Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria. J. Immun. 154, 4576-4582.
29. Lanzavecchia A. and Scheidegger D. (1987) The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immun. 17, 105-111.
30. Leo O., Foo M., Sachs D. H., Samelson L. E. and Bluestone J. A. (1987) Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. natn. Acad. Sci. U.S.A. 84, 1374-1378.
31. Mallender W. D. and Voss E. W. Jr (1994) Construction, expression, and activity of a bivalent bispecific single-chain antibody. J. biol. Chem. 269, 199-206.
32. 2 antibody prolong host survival in a murine xenograft model. Cancer Res. 51, 5716-5721.
33. Nicholls P. J., Johnson V. G., Blanford M. D. and Andrew S. M. (1993) An improved method for generating single-chain antibodies from hybridomas. J. immunol. Meth. 165, 81-91.
34. Nitta T., Sato K., Yagita H., Okumura K. and Ishii S. (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335, 368-371.
35. Perez P., Hoffman R. W., Shaw S., Bluestone J. A. and Segal D. M. (1985) Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316, 354-356.
36. Perez P., Hoffman R. W., Titus J. A. and Segal D. M. (1986) Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies. J. exp. Med. 163, 166-178.
37. Reiter Y., Brinkmann U., Kreitman R. J., Jung S. H., Lee B. and Pastan I. (1994) Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry 33, 5451-5459.
38. Renner C., Jung W., Sahin U., Denfeld R., Pohl C., Trumper L., Hartmann F., Diehl V., Van Lier R. and Pfreundschuh M. (1994) Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 264, 833-835.
39. Sachs D. H., Mayer N. and Ozato K. (1981) Hybridoma antibodies directed toward murine H-2 and Ia antigens. In Monoclonal Antibodies and T-cell Hybridomas (Edited by Hammerling J., Hammerling U. and Kearney J. F.), p.95. Elsevier/North-Holland, New York,
40. Schneider C., Sutherland R., Newman R. and Greaves M. (1982) Structural features of the cell surface receptor for transferrin that is recognized by the monoclonal antibody OKT9. J. biol. Chem. 257, 8516-8522.
41. Segal D. M., Titus J. A. and Stephany D. A. (1987) The use of fluorescence flow cytometry for the study of lymphoid cell receptors. In Methods in Enzymology: Immunological Technigues, Part K: in vitro Models of B and T Cell Function and Lymphoid Cell Receptors (Edited by Di Sabato G.), p. 478. Academic Press, New York.
42. Segal D. M., Urch C. E., George A. J. T. and Jost C. R. (1992) Bispecific antibodies in cancer treatment. In Biologic Therapy of Cancer Updates, Vol. 2 (Edited by DeVita V. T., Hellman S. and Rosenberg S. A.), p. 1. J. B. Lippincott, Philadelphia.
43. Segal D. M. (1993) SPDP crosslinking of antibodies to form heteroconjugates mediating redirected cytotoxicity. In Cytotoxic Cells; Recognition, Effector Function, Generation, and Methods (Edited by Sitkovsky M. V. and Henkart P. A.), p. 485. Birkhauser, Boston.
44. Segal D. M., Jost C. R. and George A. J. T. (1993) Targeted cellular cytotoxicity. In Cytotoxic Cells: Generation, Recognition, Effector Functions, Methods (Edited by Sitkovsky M. V. and Henkart P. A.), p. 96. Springer/Verlag, Berlin.
45. Segal D. M. and Snider D. P. (1989) Targeting and activation of cytotoxic lymphocytes. Chem. Immun. 47, 179-213.
46. Shalaby M. R., Shepard H. M., Presta L., Rodrigues M. L., Beverley P. C. L., Feldmann M. and Carter P. (1992) Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. exp. Med. 175, 217-225.
47. Staerz U. D., Kanagawa O. and Bevan M. J. (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314, 628-631.
48. Staerz U. D. and Bevan M. J. (1986) Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. natn. Acad. Sci. U.S.A. 83, 1453-1457.
49. Unkeless J. C. (1979) Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J. exp. Med. 150, 580-596.
50. Van Dijk J., Zegveld S. T., Fleuren G. J. and Warnaar S. O. (1991) Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int. J. Cancer 48, 738-743.
51. Weiner G. J., Kostelny S. A., Hillstrom J. R., Cole M. S., Link B. K., Wang S. L. and Tso J. Y. (1994) The role of T cell activation in anti-CD3 X antitumor bispecific antibody therapy. J. Immun. 152, 2385-2392.
52. Weiner G. J. and Hillstrom J. R. (1991) Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J. Immun. 147, 4035-4044.
53. Wunderlich J. R. and Shearer G. M. (1991) Induction and measurement of cytotoxic T lymphocyte activity, Unit 3.11. In Current Protocols in Immunology, Vol. 1 (Edited by Coligan J. E., Kruisbeek A. M., Margulies D. H., Shevach E. M. and Strober W.), p. 3.11.1. John Wiley and Sons, New York.